Clinical Trials
162 trialsOPTICAL
Sun Yat-sen University
TRIBE-C
Sun Yat-sen University
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
Alliance for Clinical Trials in Oncology
PREOPANC-3
Erasmus Medical Center
PHITT
University of Birmingham
A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Alliance for Clinical Trials in Oncology
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NRG Oncology
LAP100
NRG Oncology
TORCH-STAR
Fudan University
MEND-IT II
Catharina Ziekenhuis Eindhoven
Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer
Vejle Hospital
SOLARIS
Alliance for Clinical Trials in Oncology
FOBEAR
Sun Yat-sen University
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
Alliance for Clinical Trials in Oncology
CAPRI-3 GOIM
University of Campania Luigi Vanvitelli
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
Universitätsmedizin Mannheim
XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
Fudan University
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Ruijin Hospital
CIRCULATEIII
UNICANCER
GRECCAR8
Hospices Civils de Lyon
AIO-KRK-0418
Charite University, Berlin, Germany
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
Sun Yat-sen University
PREACT
Shanghai Cancer Hospital, China
AtezoTRIBE2
Gruppo Oncologico del Nord-Ovest
FOXHIPECT4
Maimónides Biomedical Research Institute of Córdoba
IROCAS
UNICANCER
LEFT-PANC
Helsinki University Central Hospital
The Sagittarius Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
CinClare
Fudan University
Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
First Affiliated Hospital of Guangxi Medical University
NACRE-2
UNICANCER
OSCAR
Federation Francophone de Cancerologie Digestive
mRCAT-III
Sir Run Run Shaw Hospital
EFFIPEC
Uppsala University
PANThEON
Gruppo Oncologico del Nord-Ovest
Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy
Tanta University
Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
Shanghai Junshi Bioscience Co., Ltd.
Pre-Operative Treatment in REseCTable COlon CanceR
Charite University, Berlin, Germany
NEEDS
Karolinska University Hospital
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
UNICANCER
CAIRO5
Dutch Colorectal Cancer Group
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
RESCUE-GC
Peking University Cancer Hospital & Institute
FLOT5
Krankenhaus Nordwest
PREVENT
Krankenhaus Nordwest
iMAGINE
Medical University of Vienna
Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients
Goethe University